Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma
NCT06692270 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2025-02-28
Summary
Tislelizumab in resectable esophageal squamous cell carcinoma
Conditions
- Esophagus Cancer
Interventions
- DRUG
-
Tislelizumab
Tislelizumab 200mg Q3W, D1 ; 2 cycles
Sponsors & Collaborators
-
Fujian Cancer Hospital
lead OTHER_GOV
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-05-15
- Primary Completion
- 2026-01-10
- Completion
- 2027-01-10
More Related Trials
-
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
NCT04974047 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction
NCT06469060 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
NCT05515315 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
NCT07039162 ·Status: RECRUITING ·Phase: PHASE2
-
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
NCT05469061 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
NCT06430658 ·Status: RECRUITING ·Phase: PHASE2
-
Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
NCT06703047 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
NCT05628610 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
NCT07317609 ·Status: RECRUITING ·Phase: PHASE1
-
Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC
NCT05394415 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
NCT06122493 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma
NCT05547828 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
NCT03783442 ·Status: COMPLETED ·Phase: PHASE3
-
Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
NCT04973306 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
NCT06354140 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）
NCT06509568 ·Status: RECRUITING ·Phase: PHASE2
-
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
NCT06965829 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer
NCT04776590 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
NCT04280822 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
NCT03957590 ·Status: COMPLETED ·Phase: PHASE3
-
Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
NCT06303583 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
NCT06056336 ·Status: RECRUITING ·Phase: PHASE2
-
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
NCT05984342 ·Status: RECRUITING ·Phase: PHASE1
-
Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC
NCT05807542 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
NCT05919030 ·Status: RECRUITING ·Phase: PHASE3